TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25099866

Group type: EXPERIMENTAL
Intervention: Enhanced-lotrafilcon A
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Enhanced-lotrafilcon B
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Enfilcon A
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Galyfilcon A
Number of subjects: 140

Group type: COMPARATOR
Intervention: Other SiHy lenses (balafilcon A, comfilcon A, enhanced-lotrafilcon A, enhanced-lotrafilcon B, enfilcon A, galyfilcon A)
Number of subjects: 140
Study: 21593283

Group type: EXPERIMENTAL
Intervention: Therapeutic dose of celiprolol (100 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microdose of celiprolol (97.5 µg)
Number of subjects: 30
Study: 18073779

Group type: EXPERIMENTAL
Intervention: 2.0 g per day PS-enriched spread
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17581778

Group type: EXPERIMENTAL
Intervention: Beta-blocker treatment withdrawn
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Beta-blocker dose reduction
Number of subjects: 3029

Group type: EXPERIMENTAL
Intervention: Beta-blocker maintained on the same dose
Number of subjects: 3029
Study: 15037890

Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol maleate fixed combination (LTFC) given once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Brimonidine twice daily and latanoprost once daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both LTFC and brimonidine/latanoprost
Number of subjects: 32
Study: 11418458

Group type: EXPERIMENTAL
Intervention: VBMCP with interferon
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: VBMCP with high-dose cyclophosphamide
Number of subjects: 504

Group type: COMPARATOR
Intervention: VBMCP alone
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: All treatment arms (VBMCP with interferon, high-dose cyclophosphamide, or VBMCP alone)
Number of subjects: 504
Study: 9249104

Group type: EXPERIMENTAL
Intervention: Midazolam premedication (0.04 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline-placebo
Number of subjects: 30
Study: 8282425

Group type: EXPERIMENTAL
Intervention: Triclosan dentifrices (0.3% Triclosan with 0.75% zinc citrate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan/Gantrez dentifrice (2% Gantrez)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triclosan/zinc citrate group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 3541714

Group type: EXPERIMENTAL
Intervention: 5 mg/kg of caffeine in solution orally
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30986140

Group type: EXPERIMENTAL
Intervention: Older hearing-impaired listeners (OHI)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Age-matched normal-hearing listeners
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Young normal-hearing listeners (YNH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Overall performance
Number of subjects: 49
Study: 26756554

Group type: EXPERIMENTAL
Intervention: 15 intra-detrusor injections of Dysport 750 U
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 30 intra-detrusor injections of Dysport 750 U
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 15 injections
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo for 30 injections
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dysport groups (both 15 and 30 injections)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Dysport groups
Number of subjects: 47
Study: 25678687

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL) treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 28
Study: 23771427

Group type: EXPERIMENTAL
Intervention: Heavy metal music
Number of subjects: 21

Group type: COMPARATOR
Intervention: Baroque music
Number of subjects: 21
Study: 20970129

Group type: EXPERIMENTAL
Intervention: Single-lumen needle retrieval (direct follicular aspiration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double-lumen needle retrieval (follicular flushing)
Number of subjects: 0
Study: 19735512

Group type: EXPERIMENTAL
Intervention: High concentration HA fillers (24 mg/mL) - Juvéderm Ultra, Ultra Plus, and 30
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Low concentration HA fillers (5.5 mg/mL) - Hylaform, Hylaform Plus, and Captique
Number of subjects: 160
Study: 17001566

Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 105
Study: 15388064

Group type: EXPERIMENTAL
Intervention: Health Related Quality of Life (HRQoL) measured using EuroQoL-5D questionnaire
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Physical problems related to care
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Psychological problems
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Burden perceived measured using Zarit scale
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Time commitment (hours per day)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Socio-sanitary help received
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Help from Alzheimer's Patient Family Associations (APFA)
Number of subjects: 268
Study: 11453908

Group type: EXPERIMENTAL
Intervention: Dithranol 2% cream + Clobetasol-17-propionate 0.05% ointment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Dithranol 2% cream + Vehicle
Number of subjects: 8
Study: 8782257

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine
Number of subjects: 24

Group type: COMPARATOR
Intervention: No cyclosporine (control group)
Number of subjects: 24
Study: 1417691

Group type: EXPERIMENTAL
Intervention: Cognitive and behavioral treatments
Number of subjects: 90

Group type: COMPARATOR
Intervention: Psychological tests (MMPI, BDI, STAI) and demographic variables
Number of subjects: 90
Study: 6373441

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dipyrone 500 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Acetylsalicylic acid 500 mg
Number of subjects: 18
Study: 31177856

Group type: EXPERIMENTAL
Intervention: Fremanezumab (subcutaneous injection, IgG2Δa)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 0
Study: 29976211

Group type: EXPERIMENTAL
Intervention: Video-based testing
Number of subjects: 93

Group type: COMPARATOR
Intervention: Text-based testing
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Video-based training
Number of subjects: 93
Study: 27348908

Group type: EXPERIMENTAL
Intervention: Acupuncture at acupoints on the axillary nerve distribution (Jianjing, Jianzhen, Jianliao, Jianyu, Quyuan, Tianzong, and trigger points in the scapular region) with Hegu needling and electric stimulation (continuous wave, 1Hz) for 30 min, once every two days for 10 treatments.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Regular acupuncture at Dazhui, Tianzhu, Houxi, and cervical Jiaji (EX-B 2) with electric stimulation at cervical Jiaji (EX-B 2) for 30 min, once every two days for 10 treatments.
Number of subjects: 80
Study: 25019969

Group type: EXPERIMENTAL
Intervention: Split-dose sodium picosulfate plus magnesium citrate (PMC)
Number of subjects: 862

Group type: COMPARATOR
Intervention: Standard-dose sodium picosulfate plus magnesium citrate (PMC)
Number of subjects: 862

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 862
Study: 21840967

Group type: EXPERIMENTAL
Intervention: Varenicline plus counselling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus counselling
Number of subjects: 0
Study: 20850778

Group type: EXPERIMENTAL
Intervention: Remote perconditioning (n = 28)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Remote preconditioning (n = 26)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (n = 27)
Number of subjects: 81
Study: 17980364

Group type: EXPERIMENTAL
Intervention: Diet and orlistat (120 mg, 3 times per day) for 24 weeks
Number of subjects: 32
Study: 15830222

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 12114416

Group type: EXPERIMENTAL
Intervention: SAM486A at a maximum tolerated dose (MTD) of 102.4 mg/m2/day
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: SAM486A
Number of subjects: 23
Study: 10399774

Group type: EXPERIMENTAL
Intervention: 0.05 mg/day of 17 beta-estradiol via skin patch
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo skin patch
Number of subjects: 12
Study: 7555469

Group type: EXPERIMENTAL
Intervention: Intensively treated (HbA1c 7.1 +/- 1.2%)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventionally treated (HbA1c 9.0 +/- 1.5%)
Number of subjects: 16
Study: 1574968

Group type: EXPERIMENTAL
Intervention: Propofol infusion 1 mg kg‐1 h‐1 preceded by a 1 mg kg‐1 bolus
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fentanyl 1 micrograms kg‐1 and diazepam 0.05 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 4028905

Group type: EXPERIMENTAL
Intervention: Ethanol 0.4 g/kg body weight
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ethanol 0.6 g/kg body weight
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ethanol 0.8 g/kg body weight
Number of subjects: 11
Study: 31870384

Group type: EXPERIMENTAL
Intervention: Individualized home-based exercise and nutrition interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29636539

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Both dietary and PA interventions
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 223
Study: 26786710

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid plus subcutaneous injections of carbon dioxide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hyaluronic acid
Number of subjects: 40
Study: 23241328

Group type: EXPERIMENTAL
Intervention: SofZia-preserved travoprost 0.004% (TravatanZ(®))
Number of subjects: 215

Group type: COMPARATOR
Intervention: BAK-preserved latanoprost 0.005% (Xalatan(®))
Number of subjects: 215
Study: 21307692

Group type: EXPERIMENTAL
Intervention: Discharge nursing intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19049337

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d for 12 months, then continued for another 12 months)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/d for 12 months after teriparatide)
Number of subjects: 507

Group type: COMPARATOR
Intervention: No active treatment (after teriparatide)
Number of subjects: 507
Study: 17097942

Group type: EXPERIMENTAL
Intervention: Celsior solution (CS), n = 40
Number of subjects: 80

Group type: COMPARATOR
Intervention: University of Wisconsin solution (UW), n = 40
Number of subjects: 80
Study: 15004581

Group type: EXPERIMENTAL
Intervention: SL biomicroscopy (SL/SL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SL and TM (SL/TM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both SL and TM
Number of subjects: 40
Study: 11709746

Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dihydralazine
Number of subjects: 0
Study: 9417503

Group type: EXPERIMENTAL
Intervention: Sodium selenite in combination with intensive decongestive physical therapy
Number of subjects: 0
Study: 8256080

Group type: EXPERIMENTAL
Intervention: 100 micrograms salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 200 mg salbutamol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 micrograms isoprenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 mg atenolol
Number of subjects: 0
Study: 3960242

Group type: EXPERIMENTAL
Intervention: Endurance exercise training (cycling, walking and jogging) for 12 months
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endurance exercise training
Number of subjects: 14
Study: 29555665

Group type: COMPARATOR
Intervention: Control diet with 2300 mg Na
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 379
Study: 27801408

Group type: EXPERIMENTAL
Intervention: Locomotor training combined with transcutaneous spinal cord stimulation (TSCS) and functional electrical stimulation (FES)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Locomotor training alone (Control group)
Number of subjects: 19
Study: 24999799

Group type: EXPERIMENTAL
Intervention: Olmesartan plus CCB
Number of subjects: 5141

Group type: COMPARATOR
Intervention: Olmesartan plus diuretic
Number of subjects: 5141
Study: 22884058

Group type: EXPERIMENTAL
Intervention: Modified Da-Cheng-Qi Decoction (DCQD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 20354030

Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥ 30 kg/m²)
Number of subjects: 1519

Group type: COMPARATOR
Intervention: Non-obese patients (BMI 18.5-29.9 kg/m²)
Number of subjects: 1519
Study: 18550978

Group type: EXPERIMENTAL
Intervention: Static stretching (SG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ballistic stretching (BG)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 29
Study: 15779642

Group type: EXPERIMENTAL
Intervention: Mepentol
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Mepentol and Placebo
Number of subjects: 331
Study: 11958353

Group type: EXPERIMENTAL
Intervention: go/no-go lexical decision task
Number of subjects: 0

Group type: COMPARATOR
Intervention: yes/no lexical decision task
Number of subjects: 0
Study: 10582256

Group type: EXPERIMENTAL
Intervention: NPPV (Non-invasive Positive Pressure Ventilation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 0
Study: 7675973

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2187668

Group type: EXPERIMENTAL
Intervention: Urokinase administered intravenously as a bolus before hospital admission (group I, n = 40)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Urokinase administered intravenously as a bolus after hospital admission (group II, n = 38)
Number of subjects: 78
Study: 6776316

Group type: EXPERIMENTAL
Intervention: Tunnelling of PVC catheters (group B)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Direct puncture technique (group A)
Number of subjects: 150
Study: 30039248

Group type: EXPERIMENTAL
Intervention: Food deprivation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control stimuli
Number of subjects: 0
Study: 30880212

Group type: EXPERIMENTAL
Intervention: Confluent bilateral cement (Group A)
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Separated bilateral cement (Group B)
Number of subjects: 1341

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 1341
Study: 28010943

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Electrocautery Technique (ET)
Number of subjects: 40
Study: 25765536

Group type: EXPERIMENTAL
Intervention: Topical tryptophan
Number of subjects: 51

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 51
Study: 24346254

Group type: EXPERIMENTAL
Intervention: Dermasilk® briefs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cotton placebo briefs
Number of subjects: 30
Study: 21246077

Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 20 wt% silica sols, and then silane coupling agent applied (Group Al20C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 30 wt% silica sols, and then silane coupling agent applied (Group Al30C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sandblasted, silica coating via sol‐gel process prepared using 40 wt% silica sols, and then silane coupling agent applied (Group Al40C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sandblasted (Group Al)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sandblasted + silane coupling agent applied (Group AlC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Groups Al20C, Al30C, and Al40C
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups after 20 days of water storage
Number of subjects: 60
Study: 19384012

Group type: EXPERIMENTAL
Intervention: Balanced Salt Solution (BSS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ringer's Lactate (RL)
Number of subjects: 90
Study: 17605780

Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg, n = 43) every six hours for a total of four doses on the day preceding extubation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (normal saline, n = 43) every six hours for a total of four doses on the day preceding extubation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg, n = 43)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo (normal saline, n = 43)
Number of subjects: 86
Study: 15115173

Group type: EXPERIMENTAL
Intervention: Self-management asthma education based on the PRECEDE-PROCEED model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular outpatient asthma education (Control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both groups (Experimental and Control)
Number of subjects: 0
Study: 11795455

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP) 32 mg per day for 6 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 4-aminopyridine (4-AP)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 9481027

Group type: EXPERIMENTAL
Intervention: Food-specific serum IgE testing for six foods (milk, egg, wheat, soy, peanut, fish)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Food challenges (36 double‐blind, placebo‐controlled, and 14 open)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: History of acute significant reactions
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Predictive levels of IgE
Number of subjects: 63
Study: 7986245

Group type: EXPERIMENTAL
Intervention: Folsan tablet (5 mg folic acid)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Folsan injection solution (reference preparation B)
Number of subjects: 17
Study: 2645385

Group type: EXPERIMENTAL
Intervention: Regimen A: discontinue therapy
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Regimen B: reinduction for 4 weeks, then discontinue therapy
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Regimen C: continue maintenance therapy for 2 more years, then discontinue
Number of subjects: 481

Group type: COMPARATOR
Intervention: All regimens (A, B, C)
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Boys randomized to discontinue therapy
Number of subjects: 481
Study: 31574157

Group type: EXPERIMENTAL
Intervention: Dural Sealant Patch (DSP)
Number of subjects: 40
Study: 31248390

Group type: EXPERIMENTAL
Intervention: Allopurinol in addition to therapeutic hypothermia
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo in addition to therapeutic hypothermia
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 28347919

Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (TRIBE cohort)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (FIRE-3 cohort)
Number of subjects: 453

Group type: COMPARATOR
Intervention: FOLFIRI and cetuximab (control cohort)
Number of subjects: 453
Study: 26674187

Group type: EXPERIMENTAL
Intervention: Standardized serving-sizes in NFts
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Descriptors or colour coding of % DV next to calories and nutrients in NFts
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Both standardized serving-sizes and descriptors of % DV in NFts
Number of subjects: 2010
Study: 23291515

Group type: EXPERIMENTAL
Intervention: Group Triple P
Number of subjects: 81

Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 81
Study: 20381654

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP level > or = 260 pg/ml
Number of subjects: 206
Study: 18420874

Group type: EXPERIMENTAL
Intervention: Magnesium with bupivacaine (group MB)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Bupivacaine (group B)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Magnesium (group M)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline placebo (group S)
Number of subjects: 108
Study: 16647139

Group type: EXPERIMENTAL
Intervention: Personality measures before and after treatment
Number of subjects: 95
Study: 14563572

Group type: EXPERIMENTAL
Intervention: Ad5FGF‐4 gene therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 10821451

Group type: EXPERIMENTAL
Intervention: Re-engineered surgical service; patients admitted on the day of surgery, guided by a clinical pathway, discharged early with domiciliary post-acute care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital in the Home care pathway; acute medical patients admitted through the Emergency Department.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pooled results from both trials; treatment group from both trials.
Number of subjects: 0
Study: 8888383

Group type: EXPERIMENTAL
Intervention: Nicotine (administered subcutaneously or by cigarette smoking)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amphetamine (5 mg administered 90 min before testing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified, but implied as subjects not receiving amphetamine)
Number of subjects: 0
Study: 1892303

Group type: EXPERIMENTAL
Intervention: formoterol 12 micrograms twice a day
Number of subjects: 145

Group type: COMPARATOR
Intervention: albuterol 200 micrograms four times a day
Number of subjects: 145
Study: 6798902

Group type: EXPERIMENTAL
Intervention: Oral sodium cromoglycate
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31183535

Group type: EXPERIMENTAL
Intervention: Physiotherapist-guided pelvic floor muscle training (PFMT) program
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unguided pelvic floor muscle training (PFMT) program
Number of subjects: 48